- Home
- FENC vs PBYI Comparison
FENC vs PBYI Comparison
Compare FENC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | PBYI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.4M | 263.4M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FENC | PBYI |
|---|---|---|
| Price | $7.44 | $6.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 120.6K | ★ 432.9K |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.67 | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | ★ $47,538,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.78 | N/A |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | ★ 123.69 | N/A |
| 52 Week Low | $4.68 | $2.58 |
| 52 Week High | $9.92 | $7.68 |
Technical Indicators
Market Signals| Indicator | FENC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 45.55 |
| Support Level | $7.44 | $5.85 |
| Resistance Level | $8.19 | $6.15 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 11.79 | 28.27 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.